The U.S. Senate passed a revised iteration of the Biosecure Act as an amendment to the National Defense Authorization Act, proposing restrictions on federal funding and contracting with ‘biotechnology companies of concern’ identified in Defense Department listings. The Senate version omits explicit company names included in prior bills, a change intended to broaden support and reduce controversy. The amendment still must be reconciled with the House NDAA, which passed without Biosecure provisions. Researchers and industry groups previously warned the earlier bill could disrupt collaborations and supply chains. The act would affect contract manufacturing, R&D partnerships and cross‑border collaborations if enacted.